top of page
KHealth Logo1-04.png
Firefly_Gemini Flash.png

FDG PET/CT Scan: Advanced Molecular Imaging for Early Cancer Detection and Personalized Care

A Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan is one of the most advanced diagnostic imaging procedures available in modern medicine. By combining two powerful imaging technologies—PET, which measures metabolic activity, and CT, which provides detailed anatomical images—an FDG PET/CT scan enables physicians to identify diseases at both the cellular and structural levels.
 

Unlike conventional imaging techniques that primarily reveal changes in the size or shape of organs, FDG PET/CT detects abnormal cellular activity before physical changes become apparent. This capability allows for earlier diagnosis, more accurate staging, and more effective treatment planning.
 

Today, FDG PET/CT has become an essential imaging modality in oncology and is also used in selected neurological, cardiac, and inflammatory conditions.

What is an FDG PET/CT Scan?

How Does FDG PET/CT Work?

The procedure uses a radiopharmaceutical called Fluorodeoxyglucose (FDG), a glucose-like compound labeled with a small amount of radioactive tracer.

Since glucose is the body's primary source of energy, cells naturally absorb it to function. Cancer cells, however, typically consume significantly more glucose than normal cells because of their rapid growth and increased metabolic activity. After FDG is injected into a vein, these highly active cells absorb more of the tracer.

The PET scanner detects the radiation emitted by the tracer and creates images showing areas of increased metabolic activity, while the CT scanner provides detailed anatomical information. Together, these images help physicians accurately locate abnormal tissues and evaluate their extent.

Cancer Staging

Knowing whether cancer has spread is essential for selecting the most appropriate treatment.

FDG PET/CT provides comprehensive whole-body imaging that helps physicians determine:

  • The size and location of the primary tumor

  • Whether nearby lymph nodes are involved

  • Whether cancer has spread to distant organs

  • The overall stage of the disease

Accurate staging helps physicians develop individualized treatment plans and avoid unnecessary procedures.

Monitoring Treatment Response

One of the greatest strengths of FDG PET/CT is its ability to evaluate how well cancer is responding to treatment.

After chemotherapy, radiation therapy, immunotherapy, or targeted therapy, physicians can compare PET/CT scans to determine whether:

  • Tumor metabolism has decreased

  • Cancer cells are no longer active

  • Additional treatment is necessary

  • Current therapy should be modified

This allows treatment decisions to be based on biological response rather than changes in tumor size alone.

Detecting Cancer Recurrence

Even after successful treatment, cancer may return.

FDG PET/CT can identify recurrent disease earlier than many conventional imaging methods by detecting renewed metabolic activity before significant structural changes develop.

Early detection of recurrence often leads to more timely treatment and improved patient outcomes.

What to Expect During the Procedure

Before the Scan

Patients will receive specific preparation instructions from their healthcare provider. In most cases, preparation includes:

  • Fasting for several hours before the examination

  • Drinking water unless otherwise instructed

  • Informing the healthcare team about current medications

  • Advising the staff if pregnant, breastfeeding, or diabetic

Blood glucose levels are typically checked before administering the radiopharmaceutical.

During the Procedure
A small amount of FDG is injected into a vein in the arm.
Patients then rest quietly for approximately 45 to 60 minutes while the tracer is distributed throughout the body. Remaining still during this uptake period is important to ensure optimal image quality.
The PET/CT scan itself generally takes between 20 and 40 minutes, during which patients lie comfortably on the scanning table while it moves slowly through the scanner.
The procedure is painless and non-invasive.

After the Scan

Patients can usually resume normal daily activities immediately unless instructed otherwise.

Drinking plenty of fluids after the examination helps eliminate the radiopharmaceutical from the body naturally through urine.

The radioactive tracer loses its activity quickly and is considered safe for routine clinical use.

Safety Information

FDG PET/CT is performed under strict safety protocols by trained nuclear medicine professionals.

The amount of radiation used is carefully calculated and kept as low as reasonably achievable while maintaining high-quality diagnostic images.

Serious allergic reactions to FDG are extremely rare.

Patients should always inform their physician if they are pregnant, breastfeeding, or have any medical conditions that may affect the examination.

bottom of page